Stefánsson BV - Search Results

1

Dapagliflozin in Patients with Chronic Kidney Disease.

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Among authors: stefansson bv. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. N Engl J Med. 2020. PMID: 32970396 Free article. Clinical Trial.

2

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.

Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sjöström CD. Fioretto P, et al. Among authors: stefansson bv. Diabetologia. 2016 Sep;59(9):2036-9. doi: 10.1007/s00125-016-4017-1. Epub 2016 Jun 15. Diabetologia. 2016. PMID: 27306615 Free PMC article. Clinical Trial. No abstract available.

3

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.

Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F. Rossignol P, et al. Among authors: stefansson bv. Eur Heart J. 2019 Mar 14;40(11):880-886. doi: 10.1093/eurheartj/ehx209. Eur Heart J. 2019. PMID: 28431138 Free PMC article.

4

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.

Dekkers CCJ, Wheeler DC, Sjöström CD, Stefansson BV, Cain V, Heerspink HJL. Dekkers CCJ, et al. Among authors: stefansson bv. Nephrol Dial Transplant. 2018 Nov 1;33(11):2005-2011. doi: 10.1093/ndt/gfx350. Nephrol Dial Transplant. 2018. PMID: 29370424 Free PMC article.

5

Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.

Dekkers CCJ, Wheeler DC, Sjöström CD, Stefansson BV, Cain V, Heerspink HJL. Dekkers CCJ, et al. Among authors: stefansson bv. Nephrol Dial Transplant. 2018 Jul 1;33(7):1280. doi: 10.1093/ndt/gfy135. Nephrol Dial Transplant. 2018. PMID: 29762740 Free PMC article. No abstract available.

6

Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus.

Go AS, Yang J, Tan TC, Cabrera CS, Stefansson BV, Greasley PJ, Ordonez JD; Kaiser Permanente Northern California CKD Outcomes Study. Go AS, et al. Among authors: stefansson bv. BMC Nephrol. 2018 Jun 22;19(1):146. doi: 10.1186/s12882-018-0942-1. BMC Nephrol. 2018. PMID: 29929484 Free PMC article.

7

Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.

Heerspink HJL, Sjöström CD, Inzucchi SE, Hallow MK, Cain VA, Rossing P, Stefansson BV, Sartipy P. Heerspink HJL, et al. Among authors: stefansson bv. Diabetes Obes Metab. 2019 Mar;21(3):720-725. doi: 10.1111/dom.13579. Epub 2018 Dec 11. Diabetes Obes Metab. 2019. PMID: 30414240 Free PMC article.

8

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.

Idzerda NMA, Stefansson BV, Pena MJ, Sjostrom DC, Wheeler DC, Heerspink HJL. Idzerda NMA, et al. Among authors: stefansson bv. Nephrol Dial Transplant. 2020 Sep 1;35(9):1570-1576. doi: 10.1093/ndt/gfz064. Nephrol Dial Transplant. 2020. PMID: 31005993 Free PMC article.

9

Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials.

Toto RD, Goldenberg R, Chertow GM, Cain V, Stefánsson BV, Sjöström CD, Sartipy P. Toto RD, et al. Among authors: stefansson bv. J Diabetes Complications. 2019 Oct;33(10):107402. doi: 10.1016/j.jdiacomp.2019.06.007. Epub 2019 Jul 2. J Diabetes Complications. 2019. PMID: 31375422 Clinical Trial.

10

The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.

Scholtes RA, van Raalte DH, Correa-Rotter R, Toto RD, Heerspink HJL, Cain V, Sjöström CD, Sartipy P, Stefánsson BV. Scholtes RA, et al. Among authors: stefansson bv. Diabetes Obes Metab. 2020 Apr;22(4):549-556. doi: 10.1111/dom.13923. Epub 2019 Dec 14. Diabetes Obes Metab. 2020. PMID: 31742881 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page